Advertisement
U.S. markets closed

Beam Therapeutics Inc. (BEAM)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
35.80+1.81 (+5.33%)
At close: 04:00PM EST
35.10 -0.70 (-1.96%)
After hours: 08:00PM EST
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bullishpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close33.99
Open33.85
Bid34.81 x 800
Ask36.00 x 800
Day's Range33.78 - 36.02
52 Week Range16.95 - 41.07
Volume1,440,347
Avg. Volume1,309,010
Market Cap2.918B
Beta (5Y Monthly)1.66
PE Ratio (TTM)N/A
EPS (TTM)-4.17
Earnings DateMay 08, 2024 - May 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est46.00
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued

Subscribe to Yahoo Finance Plus to view Fair Value for BEAM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Beam Therapeutics Inc.
    Analyst Report: Exact Sciences CorporationExact Sciences Corporation, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a pre-cancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening, too.
    Rating
    Fair Value
    Economic Moat
    4 days agoMorningstar
View more